Sao Tome and PrincipeTuberculosis profile
Population  2015 <1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–0.013) 3.6 (1.4–6.9)
Mortality (HIV+TB only) <0.01 (0–0.015) 1.3 (0–8)
Incidence  (includes HIV+TB) 0.18 (0.18–0.19) 97 (94–100)
Incidence (HIV+TB only) 0.028 (0.018–0.041) 15 (9.7–21)
Incidence (MDR/RR-TB)** 0.036 (0.026–0.046) 19 (14–24)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.012 (<0.01–0.016) 0.056 (0.042–0.07) 0.068 (0.05–0.086)
Males <0.01 (<0.01–0.01) 0.11 (0.088–0.13) 0.12 (0.092–0.14)
Total 0.019 (0.014–0.024) 0.17 (0.16–0.17) 0.18 (0.18–0.19)
TB case notifications, 2015  
Total cases notified 207
Total new and relapse 178
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 89%
          - % bacteriologically confirmed among pulmonary 38%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 96% (93–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.05 (0.01–0.12)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 24 13%
          - on antiretroviral therapy 24 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  38
(28–49)
Estimated % of TB cases with MDR/RR-TB 2.8% (0.1–6.7) 88% (47–100)  
% notified tested for rifampicin resistance 1% 69% 29
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 74% 149
Previously treated cases, excluding relapse, registered in 2014 56% 9
HIV-positive TB cases, all types, registered in 2014 54% 24
MDR/RR-TB cases started on second-line treatment in 2013 83% 6
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 4%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) <1
Funding source: 1% domestic, 75% international, 24% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data